Margherita Ambrosini, Medical Doctor, Oncology Clinical and Research Fellow at the Fondazione IRCCS National Cancer Institute in Milan, posted on LinkedIn:
“Switch maintenance with paclitaxel plus ramucirumab significantly improved key disease related symptoms and delayed clinical deterioration compared to continuation of oxaliplatin and fluoropyrimidine first line chemotherapy in patients with advanced HER2- gastric/gej cancer enrolled in the phase 3 ARMANI trial.
Pass by poster board 350 to discuss about it!”
More posts featuring ASCO25.